BRCA1 and cancer: The advent of poly(ADP-ribose) polymerase inhibitors (PARPi) has revolutionized the treatment landscape for cancers harboring homologous recombination (HR) deficiencies, particularly those resulting from BRCA1 and BRCA2 mutations1.